Associate Professor of Clinical Pathology and Laboratory Medicine, Papanicolaou Cytology Laboratory, New York-Presbyterian Hospital-Weill Cornell Medicine
Joined August 2018
- Tweets403
- Following508
- Followers456
- Likes508
Jonas Heymann retweeted
#OpenAccess! Ultrarapid BRAF mutation detection on supernatant cell-free DNA obtained by FNA: An accurate and expedient method for BRAF assessment in aggressive thyroid carcinomas
acsjournals.onlinelibrary.wi…
#CytoPath @carliesigel
Jonas Heymann retweeted
New and #OpenAccess! | Preanalytical variables affect predictive immunohistochemical biomarker testing in non–small cell lung carcinoma cytology specimens
acsjournals.onlinelibrary.wi…
#CytoPath @Sinchita_Roy @Saroja_DeviG
Jonas Heymann retweeted
Holy Grail or holy sh..t?
Very intriguing results from the PATHFINDER-2 trial with Galleri MCED test - trial does not reach its endpoint (of reducing n of 12 index st 3/4 cancers by 3 yrs) but still… notable separation of stage 4 cancer detection curves at 3 yrs+ so maybe endpoint was overoptimistic/too early?
Despite very high specificity, low prevalence yields more false neg than true pos results so similar to scanxiety…. With MCED tests we will run risk of creating a new emotion: MSAD…
In a trial of a blood-based multicancer early-detection test added to usual care, the incidence of stage III or IV cancer after three rounds of screening did not differ significantly from that with usual care alone. Full NHS-Galleri trial results: nej.md/4xRZN5L
Editorial: A Step in the Search for the Elusive Holy Grail of Early Detection of Cancer nej.md/4cK3UIy
ALT A bar chart from an Original Article published in the New England Journal of Medicine article titled "Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis." The chart shows the distribution of the route to cancer diagnosis according to trial group after three annual screening rounds. The trial name, NHS-Galleri, is in parentheses after the title. The NEJM identity sits at the bottom.
It's always difficult to differentiate the stars that are rising from those that are risen. Either way, this is a young man you should get to know! acsjournals.onlinelibrary.wi… @CancerCytopath @cytopathology @Pathologists
I sincerely hope that when @Sinchita_Roy writes her next book, she titles it "These challenges frequently manifest first within pathology departments." acsjournals.onlinelibrary.wi… @CancerCytopath @JournalCancer @IASLC @AMPath
File this under reviews that will change your perspective. And for the #molpath community, please help me wrap my head around how we can detect the alterations depicted in Fig. 4C. @TheNixonLab rdcu.be/fy0He
This is not the kind of article I usually read, but this is just. So. Cool. Finally, a concrete way to improve patient care and performance in our day-to-day jobs. acsjournals.onlinelibrary.wi… @CancerCytopath
Jonas Heymann retweeted
Early detection of cancer! Read more about it in Cancer Cytopathology!
@MGBpathology @CancerCytopath @ACSNews
doi.org/10.1002/cncy.70128
Jonas Heymann retweeted
RET mutations are the most common molecular alterations in MTC in both somatic and familial MTC, very important in treatment with target RET inhibitors, second common is RAS mutations #cytochat @CancerCytopath @bfaquin @MarcPusztaszeri @IvanaKholova @MichiyaNishino
In fair Verona . . . er, Naples (and Houston!), where we lay our scene. #Shakespeare #DNA
✉️ New Letter to the Editor | Supernatant: What’s in a name?
Without a gold standard for supernatant preparations, molecular results hardly can be compared across studies, affecting their reproducibility.
acsjournals.onlinelibrary.wi…
#CytoPath @Sinchita_Roy @pathologyfinder
Jonas Heymann retweeted
#CytoChat is back! ⚡ Join us June 18 at 11am ET as we discuss Practice Essentials of diagnostic challenges in medullary thyroid carcinoma by @MarcPusztaszeri and @ZMaleki_cyto.
acsjournals.onlinelibrary.wi…
@bfaquin @MichiyaNishino @HeymannJonas @IvanaKholova #CytoPath
In my day-to-day practice, I think *way* more about cancer #diagnostics than I do about #therapeutics. Fortunately, @bfaquin has done the thinking for me. @CancerCytopath acsjournals.onlinelibrary.wi…
Jonas Heymann retweeted
Funding cuts and vaccine technology!
Read about it in Cancer Cytopathology!
doi.org/10.1002/cncy.70096
The rates of HPV negative lesions are . . . concerning. Thank you to @AmericanCancer for continuing this important conversation around #HPV testing.
New & #OpenAccess 📄🔓 Pap testing and high-risk HPV testing for women aged 65 years and older with surgical pathology follow-up
acsjournals.onlinelibrary.wi…
@SamKhader @UPMCPathology
#CytoPath #GynPath #SurgPath
Jonas Heymann retweeted
Submit your cutting edge manuscript to Cancer Cytopathology- the leading cytology journal from the American Cancer Society!! 😃😍😃
Jonas Heymann retweeted
New and #OpenAccess! | Exploring alternatives to tumor tissue for BRCA1/2 next-generation sequencing testing in high-grade serous ovarian cancer: A 34-case series of malignant ascites
acsjournals.onlinelibrary.wi…
#CytoPath CC: @HeymannJonas
Jonas Heymann retweeted
Amazing review on PTC nuclei- a must-read for endocrine pathologists and cytopathologists!
New #OpenAccess review by N. Paul Ohori MD of @UPMCPathology et al details the fascinating history of PTC nuclei & summarizes the major events representing the paradigm shifts, classification system changes, and controversies: acsjournals.onlinelibrary.wi… #CytoPath #ENTPath
Jonas Heymann retweeted
Cancer CytoPathology!
Publish your cutting edge work in the leading cytology journal!
Jonas Heymann retweeted
New and #OpenAccess! Unraveling the nexus: Tumor mutational burden, PD-L1 expression, and oncogenic alterations in non–small cell lung cancer cytology specimens
acsjournals.onlinelibrary.wi…
#CytoPath @Sinchita_Roy @Gloria_SuraMD @UTMDAnderson
Congratulations to @elsheikhtarik and @Raodyisms for their comprehensive look at #QA in #thyroid #cytology. In case of #TLDR, see Table 3 to see how *your* lab compares! @GokozanMD @MichiyaNishino @CancerCytopath acsjournals.onlinelibrary.wi…
